Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients

2011 ◽  
Vol 25 (2) ◽  
pp. 211-218 ◽  
Author(s):  
Antonio Bellasi ◽  
Emiliana Ferramosca ◽  
Carlo Ratti ◽  
Geoffrey Block ◽  
Paolo Raggi
Keyword(s):  
Vascular Disease ◽  
Hemodialysis Patients ◽  
Cardiac Valve ◽  
Valve Calcification ◽  
Cardiac Valve Calcification

scholarly journals Aortic Artery and Cardiac Valve Calcification are Associated with Mortality in Chinese Hemodialysis Patients

2015 ◽  
Vol 128 (20) ◽  
pp. 2764-2771 ◽  
Author(s):  
Xiao-Nong Chen ◽  
Zi-Jin Chen ◽  
Xiao-Bo Ma ◽  
Bei Ding ◽  
Hua-Wei Ling ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Cardiac Valve ◽  
Valve Calcification ◽  
Aortic Artery ◽  
Cardiac Valve Calcification

scholarly journals De novo Cardiac Valve Calcification after Hemodialysis in End-Stage Renal Disease Patients Predicts Future Cardiovascular Events: A Longitudinal Cohort Study

2019 ◽  
Vol 9 (4) ◽  
pp. 229-239
Author(s):  
Fu-Jun Lin ◽  
Xi Zhang ◽  
Lu-Sheng Huang ◽  
Xin Zhou ◽  
Gang Ji ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Cox Regression ◽  
De Novo ◽  
Hemodialysis Patients ◽  
Cardiovascular Outcomes ◽  
Cardiac Valve ◽  
Major Adverse Cardiovascular Events ◽  
Valve Calcification ◽  
Increased Risk ◽  
Cardiac Valve Calcification

Background: Cardiac valve calcification (CVC) in maintenance hemodialysis patients is associated with adverse cardiovascular outcomes. However, whether de novo CVC in incident hemodialysis patients predicts future cardiovascular events is unknown. Methods: This study included 174 patients newly receiving hemodialysis without CVC as reflected by echocardiography between January 2005 and December 2014. De novo CVC was determined with echocardiography once every 6 months until December 2016. Results: The median follow-up was 66 months (range, 19–141). De novo CVC developed in 80 out of 174 (45.98%) subjects: 58 developed aortic valve calcification (AVC) alone, 42 developed mitral valve calcification (MVC) alone, and 20 developed both AVC and MVC. The median time from baseline to de novo CVC was 46 months (range, 3–120) for AVC and 50 months (range, 13–127) for MVC. Patients who developed CVC had a higher major adverse cardiovascular events (MACE) rate than those who did not (AVC: 30/58 [51.72%] vs. 23/116 [19.83%]; MVC: 25/42 [59.52%] vs. 28/132 [21.21%]). Multivariate time-dependent Cox regression showed an association between MACE with both de novo AVC and MVC (AVC: hazard ratio [HR] 3.2, 95% confidence interval [CI] 1.55–6.63; MVC: HR 5.95, 95% CI 2.90–12.20). Conclusions: De novo CVC is an independent risk factor for MACE in hemodialysis patients, and regular CVC screening among hemodialysis patients without preexisting CVC may be helpful to identify patients at increased risk of adverse cardiovascular outcomes.

Association of Cardiac Valve Calcification and Inflammation in Patients on Hemodialysis

Renal Failure ◽  
2005 ◽  
Vol 27 (2) ◽  
pp. 221-226 ◽  
Author(s):  
Dilek Torun ◽  
Siren Sezer ◽  
Mehmet Baltalı ◽  
Fatma Ulku Adam ◽  
Abdullah Erdem ◽  
...  
Keyword(s):  
Cardiac Valve ◽  
Valve Calcification ◽  
Cardiac Valve Calcification

Malnutrition as a risk factor for cardiac valve calcification in patients under maintenance dialysis: a cross-sectional study

2020 ◽  
Vol 52 (11) ◽  
pp. 2205-2212
Author(s):  
Petrini Plytzanopoulou ◽  
Marios Papasotiriou ◽  
Panayiotis Politis ◽  
Christophoros Parissis ◽  
Pinelopi Paraskevopoulou ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cross Sectional Study ◽  
Cardiac Valve ◽  
Sectional Study ◽  
Cross Sectional ◽  
Valve Calcification ◽  
Cardiac Valve Calcification ◽  
Maintenance Dialysis

scholarly journals MO741TUMOR NECROSIS FACTOR ALPHA AND MAGNESIUM ARE LINKED TO CARDIAC VALVE CALCIFICATION IN DIABETIC HEMODIALYSIS PATIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Oleksandr Susla ◽  
Zoriana Litovkina ◽  
Ihor Mysula ◽  
Anatoliy Gozhenko
Keyword(s):  
Cardiovascular Risk ◽  
Chronic Inflammation ◽  
Cardiac Valve ◽  
Diabetic Patients ◽  
Necrosis Factor Alpha ◽  
Valve Calcification ◽  
Tnf Α ◽  
Cardiac Valve Calcification ◽  
Factor Alpha ◽  
Necrosis Factor

Abstract Background and Aims The processes of cardiac valve calcification (CVC) in diabetic hemodialysis (HD) patients are not fully understood. In this context, it is reasonable to complex and comprehensively research the activity of chronic inflammation and magnesium (Mg) imbalance as cardiovascular risk factors in end-stage renal disease (ESRD). The main purpose of the current study was to determine the relationship of tumor necrosis factor alpha (TNF-α) and Mg levels with the presence and severity of CVC in diabetic patients with ESRD. Method We enrolled 136 patients undergoing HD (male/female, 78/58;age, 53.9±1.0 years; HD duration, 47.6±4.2 month) in this observational cross-sectional study. The study was performed in accordance with the provisions of the Declaration of Helsinki last revision. Depending on the presence of type 2 diabetes mellitus (T2DM) all subjects were divided into two groups: the 1st one – non-diabetic patients (n=88); the 2nd one – diabetic patients (n=48). Presence of CVC was detected by ultrasound. The mitral (MVC) and aortic (AVC) valve calcification degree were scored as follows: 1, no calcification; 2, valve thickening without calcification; 3, valve annulus or cusps calcification. Serum content of TNF-α as one of the key proinflammatory cytokine was determined by enzyme-linked immunosorbent assay. Serum Mg concentration was estimated by biochemical method. Data are expressed as means±SEM. Used nonparametric statistics methods: Mann-Whitney U-test, χ2-test, Spearman’s rank R correlations. Results In diabetic HD patients TNF-α content was higher (13.86±1.34 vs. 8.73±0.60 ng/L; Z=3.04, p=0.002) whereas Mg concentration (0.87±0.02 vs. 1.00±0.02 mmol/L; Z=4.91, p<0.001) – lower compared to non-diabetic ones, and in 2nd group indices of TNF-α and Mg were related (Rs=-0.68, p<0.001). CVC was detected in 66.6% of T2DM patients with predominance of calcification of both valves (35.4%) over isolated MVC (20.8%) and AVC (10.4%). Combined MVC and AVC in the 2nd group was observed 2.6 times more often (χ2=8.78, p=0.003) than in the 1st one. For the first time it was established that in diabetic patients with ESRD the presence of CVC closely associated with indices of TNF-α (Rs=0.51, p<0.001) and Mg (Rs=-0.57, p<0.001). The MVC as well as AVC degree were related with the content of TNF-α (Rs=0.49, p<0.001; Rs=0.52, p<0.001) and Mg concentration (Rs=-0.47, p<0.001; Rs=-0.50, p<0.001) respectively. Conclusion (1) T2DM in HD patients is characterized with an increase of serum TNF-α activity and simultaneous decreased of Mg content. (2) In diabetic patients with ESRD, both MVC and AVC are closely linked with the TNF-α accumulation and hypomagnesemia. (3) Chronic inflammation and Mg deficiency can be important factors of CVC progression and very high cardiovascular risk in diabetic HD patients.

Sign in / Sign up

Export Citation Format

Share Document